what people report and what the record cautions

The short version

AOD-9604 is a growth-hormone fragment that was engineered to mobilise fat without engaging the growth-hormone receptor. In fat-cell and rodent models the mechanism is well-documented. In people it was disappointing: the pivotal 24-week obesity trial enrolled roughly 900 adults and did not beat placebo on weight loss. That is the honest entry point.

In the research-use community, the dominant report matches the clinical finding — most people describe little or no fat reduction. The molecule's safety story, however, is unusually clean: six trials found it indistinguishable from placebo on tolerability, without the water retention, IGF-1 elevation, or glucose-tolerance shift that come with full growth hormone. Below, the community layer is labeled anecdotal; the clinical cautions are cited. They are different kinds of evidence and should not be mixed.

What people report

These are effects described by the research-use community — anecdotal, not clinical evidence, not verified by controlled trials, and presented here without doses or endorsement. The most common report goes first.

The dominant report: no noticeable fat loss. By far the most frequently described outcome in fat-loss and biohacker forums is that people simply did not see meaningful body-fat reduction. That is consistent with the human obesity trials, which did not separate from placebo.

Reported upsides (anecdotal):

• Well tolerated overall. Most users describe few day-to-day complaints — echoing the published trial finding that side effects were hard to distinguish from placebo.
• No growth-hormone-type side effects. People who have used growth hormone or secretagogues often note the absence of the water retention, joint puffiness, and tingling they associate with raising IGF-1.
• No water retention or bloating. A frequent comment is the absence of the puffy look some growth-hormone protocols produce — which fits the receptor-sparing design.
• Mild energy or sense of well-being. A subset describe a vague lift; this is anecdotal, easily explained by expectation or a concurrent diet change, and was not an endpoint the failed trials measured.
• Reduced appetite (uncertain). Some report eating a little less, but this is just as likely to come from the calorie-deficit programme started at the same time.
• Better results only alongside diet and training. Those who report any visible change almost always credit a calorie deficit and structured exercise running in parallel — making it impossible to attribute the result to the peptide.

Reported downsides (anecdotal):

• Injection-site redness or irritation. Occasional reports of a small red or tender spot at the injection site that settles on its own — a generic reaction to subcutaneous peptide injection rather than a drug-specific effect.
• No effect on strength, recovery, or muscle. Unlike growth hormone, users generally report no performance or muscle changes, consistent with it not engaging the growth-hormone receptor.
• Spot fat-loss claims are implausible. Community lore that injecting near a stubborn area melts fat there specifically is biologically implausible; bodies do not lose fat by injection location, and no human trial supports it.
• Disappointment relative to marketing. Clinicians and longtime users repeatedly note that the "fat-loss peptide" framing oversells what people actually experience.
• Research-grade product quality. Experienced users caution that gray-market vials vary widely in purity and identity, so any reported effect — or lack of one — may reflect the contents rather than the molecule.

Safety and cautions

These cautions are grounded in the published literature and cited below. They are a different kind of evidence from the community reports above.

• Investigational, not approved for any use. AOD-9604 was developed as an oral anti-obesity drug candidate but never gained marketing approval. It carries no approved indication, dosing standard, or quality benchmark, so all use is experimental and unverified for human treatment ^[23].
• Human fat-loss efficacy was not demonstrated. Despite encouraging rodent data, the pivotal human obesity trials did not show statistically significant weight loss versus placebo, and the development programme was discontinued — expectations of fat loss are not supported by the clinical record ^[24].
• The fat-metabolism mechanism is largely preclinical and indirect. Acetyl-CoA carboxylase inhibition, beta-3 adrenergic receptor up-regulation, and increased fat oxidation were characterised mainly in mouse, rat, and cell models and have not translated into a proven human fat-loss effect ^[1].
• Rodent efficacy does not equal human benefit. Chronic dosing reduced body weight and fat in obese mice and required functional beta-3 adrenergic signalling — but the rodent-to-human jump failed here, which is exactly why preclinical fat-loss results should not be read as human evidence ^[3].
• Limited long-term human safety data. The longest published human trial ran roughly 24 weeks. Tolerability resembled placebo, but there is no long-term or large-scale safety surveillance, so chronic and rare risks remain uncharacterised ^[23].
• Situate it among unproven obesity drug candidates. Reviews of the obesity-pharmacotherapy landscape place lipolytic growth-hormone-fragment approaches like AOD-9604 among many candidates that looked mechanistically promising yet did not reach approved use — a common pattern, not unique to this molecule ^[25].
• WADA Section S2 prohibition. As a growth-hormone fragment, AOD-9604 is prohibited at all times in sport under WADA Section S2. Dedicated LC-MS/MS assays can detect it in urine; it does not interfere with the standard hGH isoform immunoassay, so its use is not captured by that particular test but is still a prohibited-substance violation ^[16].

Then and now: from Monash to a shelved obesity programme

AOD-9604 originated from work at Monash University that identified the C-terminal region of human growth hormone (around residues 176–191) as the domain responsible for the hormone's fat-metabolising activity. Metabolic Pharmaceuticals (Australia) developed it as an orally dosed anti-obesity drug candidate and ran several randomised, placebo-controlled trials in obese adults through the 2000s. The pivotal Phase IIb obesity trial did not produce significant weight loss versus placebo, and the obesity development programme was discontinued around 2007 ^[23]. The molecule was later repositioned toward a nutraceutical pathway (GRAS self-affirmation at approximately 1 mg per serving) and toward preclinical intra-articular cartilage and osteoarthritis work that produced one published rabbit study but no registered human trial. In December 2024, the FDA Pharmacy Compounding Advisory Committee voted not to add AOD-9604 to the 503A Bulk Drug Substances List, closing the legal U.S. compounding route.